AB toxin

Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project

Retrieved on: 
Venerdì, Aprile 26, 2024
Spasticity, Bacteriology, WARF, University, Dystonia, Publication, Partnership, Research, AB toxin, Hannover Medical School, Movement disorder, Professional, Acquisition, Jan Vansina, Hyperhidrosis, Migraine, Wisconsin Alumni Research Foundation, Canning

SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.

Key Points: 
  • SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join WizMedi Bio's new botulinum toxin development project.
  • The long-standing collaboration between Dr. Johnson and Professor Dressler has shaped the global botulinum toxin landscape over the past decades.
  • Dr. Johnson, a retired professor of bacteriology at the University of Wisconsin-Madison in the US, has dedicated over four decades to botulinum toxin research, authoring over 200 publications and founded 3 botulinum toxin companies.
  • Having introduced most of the major botulinum toxin drugs to the international markets, he is a highly sought-after consultant to the botulinum toxin industry.

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Retrieved on: 
Mercoledì, Aprile 17, 2024
Pharmaceutical, Health, Clinical Trials, Sale, Safety, MD, Patient, AB toxin, Aesthetic Surgery Journal, GLS, Overalls, Pharmaceutical industry

The “extra-strength” glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.

Key Points: 
  • The “extra-strength” glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction.
  • The study has three arms: Jeuveau® Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau® 20U.
  • The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified.
  • “This publication provides the details of the study design along with the efficacy and safety data from the Phase 2 Jeuveau extra-strength study and makes it accessible to all,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D of Evolus.

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Retrieved on: 
Martedì, Marzo 19, 2024
AEON, MMD, Patent, Caregiver, Headache, Migraine, Patient, Injection, Safety, AB toxin, Phase II, FDA, Food, MHD, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced a productive end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) following the Phase 2 data in episodic migraine previously released in October 2023, that supports advancing ABP-450 (prabotulinumtoxinA) injection into the proposed pivotal Phase 3 program. As part of the updated development plan, the Company will now conduct an interim analysis of the ongoing Phase 2 study of ABP-450 for the preventive treatment of chronic migraine and anticipates releasing the data in the second quarter of 2024.

Key Points: 
  • Patients have at least a one-year history of migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.
  • All patients will receive two treatment cycles 12 weeks apart utilizing the Company’s patented treatment paradigm (U.S. Patent No.
  • 11,826,405) involving fewer injections than the current botulinum toxin treatment option for migraine.
  • The interim analysis will include approximately 100 chronic migraine patients in each of the three arms that have completed the two 12-week treatment cycles.

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Retrieved on: 
Martedì, Marzo 19, 2024
AEON, Private placement, Private, LTD, FPA, Sale, Migraine, Note, Alembic Pharmaceuticals, AB toxin, Food, FDA, Pharmaceutical industry

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE AMEX: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the “Investment Amount”) aggregate principal amount of senior secured convertible notes (the "Notes") with Daewoong Pharmaceutical Co., LTD. Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements. The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024. Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes. Upon funding of the second installment of the Investment Amount, the Company will appoint one designee of Daewoong to the AEON Board of Directors, subject to a customary due diligence process by AEON. The Daewoong designee must be a member of Daewoong’s senior management team.

Key Points: 
  • Proceeds from the Private Placement will be paid in a first installment of $5 million and a second installment of $10 million, in each case subject to the closing conditions set forth in the agreements.
  • The Company expects the first installment to close before the end of March 2024 and the second to close in April 2024.
  • Proceeds from the Private Placement will be used to support the late-stage clinical development of ABP-450 and for general working capital purposes.
  • Concurrent with the execution of the agreements for the Private Placement, the Company terminated its forward purchase agreements (each an “FPA” and the counterparties thereto, together, the “FPA Providers”).

Merz Aesthetics® Continues Multi-Year ‘Beauty on Your Terms’ Campaign for XEOMIN® (incobotulinumtoxinA) with Announcement of Demi Lovato as New Brand Partner

Retrieved on: 
Mercoledì, Marzo 6, 2024
Cosmetics, Retail, Other Health, Pharmaceutical, Surgery, General Entertainment, Other Consumer, Celebrity, General Health, Women, Music, Hispanic, Entertainment, Consumer, Health, Summer, Multimedia, FDA, News, AB toxin, Demi Lovato, Merz, Loyalty program, Billboard, Spotify, Beauty, Partnership, Tourism

Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, today announced the latest extension of their first-of-its kind, multi-year campaign, ‘Beauty on Your Terms’ with the addition of award-winning actor and musician Demi Lovato as the newest XEOMIN® (incobotulinumtoxinA) brand partner.

Key Points: 
  • Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, today announced the latest extension of their first-of-its kind, multi-year campaign, ‘Beauty on Your Terms’ with the addition of award-winning actor and musician Demi Lovato as the newest XEOMIN® (incobotulinumtoxinA) brand partner.
  • View the full release here: https://www.businesswire.com/news/home/20240306431486/en/
    Merz Aesthetics® announces Demi Lovato as new Xeomin® (incobotulinumtoxinA) brand partner (Photo: Business Wire)
    The partnership with Lovato is a continuation of Merz Aesthetics’ multi-channel, digital-first ‘Beauty on Your Terms’ campaign, which has reimagined traditional pharmaceutical marketing strategy.
  • “Part of that is also being mindful of what goes into the products you choose to use.
  • Follow @XeominAesthetic to stay up to speed on the latest news from Demi Lovato.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
Lunedì, Marzo 4, 2024
Food and Drug Administration, Headache, MD, AB toxin, Catherine Disher, FDA, Blinking, Food, Vitamin, Dizziness, Hugel & Fils, Risk, Allergy, Human, Telecanthus, Rash, Patient, Skin infection, Child, Bleeding, Medication, Wheeze, Face, Pharmaceutical industry

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Retrieved on: 
Giovedì, Gennaio 18, 2024
AEON, Clavicle, Patient, Heart rate, Research, PTSD, Post-traumatic stress disorder, AB toxin, Stellate ganglion, OLE, Neck, DSM-IV codes, Torticollis, Safety, INA, DBP, Head, Botulinum toxin, Lidocaine, IND, Ptosis, FDA, Toxicity, Rat, SGB, Acute stress disorder, Data, Week, Anatomy, Pharmaceutical industry

IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Key Points: 
  • ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
  • These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
  • “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
  • The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.

Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

Retrieved on: 
Martedì, Gennaio 23, 2024
Senior, Patient, ABBV, AB toxin, Business, VIP, Cosmetic, RL, Human, A-list, AbbVie

IRVINE, Calif., Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve months affirmed Allē's position as the leading aesthetics loyalty rewards program in the country, with a ninety-two percent satisfaction rate reported by survey respondents1*.

Key Points: 
  • IRVINE, Calif., Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program.
  • From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program in the category.
  • That's why Allē is the first and only aesthetics loyalty rewards program to give its users points on more than 40 brands, products, and treatments at their Allē provider—even those that are not Allē brands.
  • For providers looking to engage with Allē for Business, please contact your local Allergan Aesthetics Business Development Manager.

PatientFi Appoints Ray Bassi as New Senior Vice President, Sales

Retrieved on: 
Lunedì, Gennaio 8, 2024
Practice Management, Payments, Finance, Health, Health Technology, Professional Services, Technology, Fintech, Entrepreneurship, Dermatology, AB toxin, Allergan, Growth, Patient, Deoxycholic acid, Hyperhidrosis, AbbVie, Senior, Pharmaceutical industry

PatientFi , the company which offers healthcare practices payment plans and membership solutions to increase affordability for elective procedures, today announced that aesthetic industry veteran Ray Bassi has joined the company as Senior Vice President, Sales.

Key Points: 
  • PatientFi , the company which offers healthcare practices payment plans and membership solutions to increase affordability for elective procedures, today announced that aesthetic industry veteran Ray Bassi has joined the company as Senior Vice President, Sales.
  • Prior to leaving Allergan Aesthetics, Ray served as Vice President of Sales, overseeing the U.S. injectable portfolio sales team, comprised of 300+ employees.
  • Ray joined Dermira, after leaving Allergan, as Vice President of Sales where he helped launch QBREXZA, a topical treatment for axillary hyperhidrosis.
  • Prior to joining PatientFi, Ray served as Vice President of Sales for DermTech, a skin genomics company, where he led the expansion of the sales organization.